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Abstract
 
The regulation of liver apolipoprotein (apo) A-I gene ex-
pression by fibrates was studied in human apo A-I trans-
genic mice containing a human genomic DNA fragment
driving apo A-I expression in liver. Treatment with fenofi-
brate (0.5% wt/wt) for 7 d increased plasma human apo A-I
levels up to 750% and HDL-cholesterol levels up to 200%
with a shift to larger particles. The increase in human apo
A-I plasma levels was time and dose dependent and was al-
ready evident after 3 d at the highest dose (0.5% wt/wt) of
fenofibrate. In contrast, plasma mouse apo A-I concentra-
tion was decreased after fenofibrate in nontransgenic mice.
The increase in plasma human apo A-I levels after fenofi-
brate treatment was associated with a 97% increase in he-
patic human apo A-I mRNA, whereas mouse apo A-I
mRNA levels decreased to 51%. In nontransgenic mice, a
similar down-regulation of hepatic apo A-I mRNA levels
was observed. Nuclear run-on experiments demonstrated
that the increase in human apo A-I and the decrease in
mouse apo A-I gene expression after fenofibrate occurred at
the transcriptional level. Since part of the effects of fibrates
are mediated through the nuclear receptor PPAR (peroxi-
some proliferator-activated receptor), the expression of the
acyl CoA oxidase (ACO) gene was measured as a control of
PPAR activation. Both in transgenic and nontransgenic
mice, fenofibrate induced ACO mRNA levels up to sixfold.
When transgenic mice were treated with gemfibrozil (0.5%
wt/wt) plasma human apo A-I and HDL-cholesterol levels
increased 32 and 73%, respectively, above control levels.
The weaker effect of this compound on human apo A-I and
HDL-cholesterol levels correlated with a less pronounced
impact on ACO mRNA levels (a threefold increase) suggest-
ing that the level of induction of human apo A-I gene is re-
lated to the PPAR activating potency of the fibrate used.
Treatment of human primary hepatocytes with fenofibric
acid (500 
 
m
 
M) provoked an 83 and 50% increase in apo A-I
secretion and mRNA levels, respectively, supporting that a
direct action of fibrates on liver human apo A-I production
leads to the observed increase in plasma apo A-I and HDL-
cholesterol. (
 
J. Clin. Invest.
 
 1996. 97:2408–2416.) Key
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Introduction
 
Numerous epidemiological data have demonstrated that apoli-
poprotein A-I, the major protein component of high density li-
poproteins (HDLs), is linked to a low risk for development of
coronary artery disease (1–3). Furthermore, increased produc-
tion of human apo A-I by the liver in transgenic mice has been
shown to confer protection against early atherogenesis (4).
Apolipoprotein gene expression can be modulated by dif-
ferent effectors such as fatty acids, hormones, and hypolip-
idemic drugs. Widely used in the treatment of hyperlipidemia
(5, 6), fibrates decrease plasma cholesterol and triglyceride
concentrations by accelerating VLDL catabolism via a combi-
nation of lipoprotein lipase activation and apo C-III reduction
and by decreasing hepatic VLDL secretion (7–10). Fibric acid
derivatives are further known as peroxisome proliferators in
rodents, but not in humans (11, 12). These drugs primarily in-
crease the transcription of many genes encoding peroxisomal
proteins such as the enzymes responsible for the 
 
b
 
-oxidation of
the long-chain fatty acids (13–17). In addition, chronic expo-
sure of rodents to fibrates can lead to hepatomegaly and hepa-
tocarcinogenesis (18). Several lines of evidence now suggest
that most activities of peroxisomal proliferators including fi-
brates are essentially mediated by the peroxisome proliferator-
activated receptors (PPAR),
 
1
 
 which belong to the nuclear hor-
mone receptor gene superfamily (19–23).
In rodents, fibrates decrease liver apo A-I mRNA and
plasma concentrations (24). Using primary cultures of adult rat
hepatocytes, we recently demonstrated that the negative effect
of fibrates on apo A-I gene expression results from a direct ac-
tion on hepatic gene transcription (25). In humans, treatment
with fibrates is consistently associated with an increase in
plasma HDL-cholesterol and apo A-I concentrations (5, 26–29).
Transgenic mice overexpressing the human apo A-I gene in
liver display human-like HDL particles in plasma (30, 31) and
thus provide an excellent means to study the in vivo regulation
of apo A-I expression by fibrates and its consequences on
plasma HDL concentrations. We report here that fibrates in-
duce human apo A-I and reduce mouse apo A-I gene expres-
sion in transgenic mice. Experiments on human primary hepa-
tocytes indicate that fibrates increase apo A-I production
through a direct action on cells. Moreover, nuclear run-on ex-
periments demonstrate that the effects of fenofibrate on hu-
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man and mouse apo A-I gene expression occur at the tran-
scriptional level. These results therefore suggest that the
species-specific differences on apo A-I gene expression are
due to different 
 
cis
 
-acting elements in the human and mouse
genes.
 
Methods
 
Animals.
 
Two different human apo A-I transgenic mice lines were
used in this study. The human apo A-I transgenic C57BL/6 mice line
A2 contains 21 copies of an 11-kb human apo A-I genomic DNA
fragment (31), whereas the second human apo A-I transgenic mice
line (purchased from Charles River Laboratories, Wilmington, MA)
contains a 2.2-kb human apo A-I genomic DNA fragment (30). Both
lines contain the liver-specific enhancer of the human apo A-I gene
promoter necessary to drive hepatic apo A-I expression (30, 31).
2-mo-old male transgenic mice and nontransgenic littermates (con-
trol) were treated with fenofibrate or gemfibrozil (Sigma Chemical
Co., St. Louis, MO) mixed in mouse chow at the indicated concentra-
tions (wt/wt). Body weights and food intake of the mice, determined
every day throughout the treatment period to assess a potential toxic
side effect, did not differ between treated and control animals. Blood
was taken at the beginning and at the end of the experiment from the
retroorbital plexus from 4-h fasted mice. Plasma was separated by
centrifugation at 2,000 
 
g
 
 for 15 min and kept at 4
 
8
 
C until analysis
within 1 wk. At the end of the experiment animals were killed, and
livers were removed immediately, rinsed in 0.9% saline, and frozen in
liquid nitrogen before RNA extraction.
 
Hepatocyte isolation and culture.
 
Human hepatocytes were ob-
tained by a two-step collagenase perfusion of liver pieces resected for
secondary hepatomas (32). Experimental procedures were approved
by the National Ethics Committee (France). Cell viability was 70–
85% as estimated by the trypan blue exclusion test. Hepatocytes were
plated at a density of 3 
 
3 
 
10
 
6
 
 cells/3 ml medium per 25-cm
 
2
 
 plastic cul-
ture dish in 75% MEM/25% medium 199, supplemented with 10%
FCS, BSA (1 mg/ml) and bovine insulin (10 
 
m
 
g/ml). Cells were incu-
bated at 37
 
8
 
C in a humidified atmosphere of 5% CO
 
2
 
/95% air. After
a 20-h attachment period, medium supplemented with dexametha-
sone (0.1 
 
m
 
M) was added and renewed daily thereafter. The cells
were exposed to fenofibric acid (synthesized at Rhône-Poulenc Rorer
Ltd., Dagenham, UK) in 0.1% DMSO, at the first medium renewal as
well as 24 and 48 h later. Control cultures received the same concen-
tration of solvent (0.1% DMSO). 20 h after the last addition of drug,
media were collected and stored at 
 
2
 
80
 
8
 
C until apolipoprotein and
protein determinations were made. Cell monolayers were washed
with cold PBS and solubilized in 4 M guanidinium isothiocyanate.
 
Plasma lipid and lipoprotein measurements.
 
HDL was separated from
apo B–containing lipoproteins by dextran sulfate precipitation. Cho-
lesterol was measured enzymatically using a commercially available
cholesterol kit (Boehringer Mannheim Biochemicals, Indianapolis,
IN) and spectrophotometrically quantified on a microplate reader
(EL 311; Bio-Teck Instruments, Winooski, VT).
Lipoprotein distribution was assayed by analytical gel filtration
chromatography. Plasma was applied to a prepacked Superose 6 HR
10/30 column (Pharmacia Fine Chemicals, Uppsala, Sweden), chro-
matographed at a flow rate of 0.4 ml min in 10 mM Tris-HCl, pH 7.4,
0.15 M NaCl, and 1 mM EDTA buffer, and monitored at 280 mm.
This system allows separation of three distinct elution peaks corre-
sponding to three major lipoprotein classes: VLDL, LDL, and HDL.
Cholesterol in the eluted fractions was measured as described above.
Eluted fractions were also set on a 4–20% acrylamide gradient SDS-
PAGE gels and transferred to a nylon membrane. A Western blot
was performed using specific human apo A-I antibodies (33).
 
Protein quantification.
 
Plasma levels of mouse and human apo A-I
were determined by rocket immunoelectrophoresis using specific
rabbit polyclonal antibodies. There was no cross-species reactivity be-
tween mouse and human apo A-I.
Apo A-I and apo A-II protein levels in human hepatocyte culture
medium were measured by a sandwich ELISA as previously de-
scribed (33). Transferrin levels were measured by a competitive
ELISA as described (34).
 
RNA analysis.
 
RNA was isolated from liver and cultured cells by
the acid guanidinium thiocyanate/phenol/chloroform method (35).
Northern and dot blot of total cellular RNA were performed as de-
scribed (36). For RNA hybridization, a specific human apo A-I
cDNA probe was used (37). A mouse apo A-I cDNA fragment was
cloned from mouse liver mRNA by reverse transcription and PCR-
amplification (sense primer: GAC AGC GGC AGA GAC TAT
GTG TCC CAG TTT GAA; antisense primer: TGG CTT TCT CGC
CAA GTG TCT TCA GGT GG). Hybridization of northern blots
containing HepG2 and nontransgenic mouse liver RNA as controls
for human and mouse apo A-I mRNA, respectively, revealed no
cross-hybridization between human and mouse apo A-I under the hy-
bridization and washing conditions used. An acyl CoA oxidase
(ACO) cDNA probe (38) was used as a control for PPAR mediated
transcriptional activation by fibrates (20), and a transferrin probe was
used as a control probe for primary cultures of human hepatocytes
(39). All probes were labeled by random primed labeling (rediprime
kit; Amersham International, Buckinghamshire, UK). Filters were
hybridized overnight to 10
 
6
 
 cpm/ml of each probe as described (36).
They were washed in 0.5 
 
3
 
 SSC and 0.1% SDS for 10 min at room
temperature and twice for 30 min at 65
 
8
 
C and subsequently exposed
to x-ray film (X-OMAT-AR; Eastman Kodak Co., Rochester, NY).
Autoradiograms were analyzed by quantification scanning densitom-
etry (GS-300 scanning densitometer; Hoefer Scientific Instruments,
San Francisco, CA) as previously described (36).
 
Isolation of nuclei and transcriptional rate assay.
 
Nuclei were pre-
pared from whole liver of transgenic and nontransgenic mice un-
treated or treated for 5 d with fenofibrate 0.5% (wt/wt). Nuclei were
resuspended in 200 
 
m
 
l of storage buffer (40% glycerol, 50 mM Tris-HCl,
pH 8.3, 5 mM MgCl
 
2
 
 and 0.1 mM EDTA). Transcription run-on as-
says were performed as described by Nevins (40), using 100 
 
m
 
l of nu-
clei. Equivalent counts of nuclear RNA labeled with [
 
a
 
-
 
32
 
P]UTP
(3,000 Ci/mmol) were hybridized for 36 h at 65
 
8
 
C to 5 
 
m
 
g human (37)
and mouse apo A-I cDNAs immobilized on Hybond-C Extra filters
(Amersham Corp.). The empty vector plasmid was used as a negative
control. After hybridization, filters were washed in 0.5
 
3
 
 SSC and
0.1% SDS for 10 min at room temperature and twice for 30 min at
65
 
8
 
C an exposed to x-ray film (X-OMAT-AR). Autoradiograms were
analyzed by quantification scanning densitometry.
 
Results
 
Effect of fenofibrate on plasma apo A-I concentrations and li-
poprotein composition.
 
Human apo A-I (hA-I) transgenic and
nontransgenic mice were treated for 7 d with fenofibrate 0.5%
(wt/wt) mixed in mouse chow. In transgenic mice, treatment
with fenofibrate resulted in a 760% increase in plasma human
apo A-I concentrations (Table I). By contrast, in nontrans-
genic mice, plasma mouse apo A-I levels were decreased by
41% (Table I). In hA-I transgenic mice, endogenous plasma
mouse apo A-I was undetectable, as previously described (31).
Gel filtration chromatography was performed to analyze
the distribution of lipoproteins in plasma of transgenic and
nontransgenic mice treated with fenofibrate. In hA-I trans-
genic mice, total plasma cholesterol levels were increased up
to 260% of controls after fenofibrate treatment (Table II).
This increase in plasma cholesterol concentration was due to
an increase in HDL-cholesterol to 300% of control (Table II).
More specifically, the cholesterol profile showed an increase of
HDL particle size, whereas VLDL and LDL particles de-
creased to undetectable levels (Fig. 1). In nontransgenic mice,
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no significant changes in total cholesterol as well as in HDL-
cholesterol levels were observed after fenofibrate treatment
(Table II) thereby confirming previous results (41).
To further characterize HDL particles formed in transgenic
mice after fenofibrate treatment, proteins in the different
eluted fractions were separated on a 4–20% SDS polyacryl-
amide gradient gel. Western blot analysis confirmed that hu-
man apo A-I was present in the HDL particle fractions (data
not shown). This confirms that the increase in circulating apo
A-I is associated with the appearance of large HDL particles.
 
Effect of fenofibrate on apo A-I gene expression in human
apo A-I transgenic and nontransgenic mice.
 
We next investi-
gated whether the increase in plasma human apo A-I levels ob-
served after fenofibrate treatment was due to an increase in liver
apo A-I gene expression. In transgenic mice, treatment with
fenofibrate resulted in a 97% increase in liver human apo A-I
mRNA levels, whereas liver endogenous mouse apo A-I
mRNA levels were reduced by 49% compared to untreated
mice. In nontransgenic mice, a similar decrease in mouse apo
A-I mRNA levels was obtained after fenofibrate administra-
tion (Fig. 2 
 
A
 
). This opposite effect of fenofibrate on human
and mouse apo A-I mRNA levels measured by dot blot hy-
bridization was confirmed by Northern blot analysis (Fig. 2 
 
B
 
).
A comparable increase in liver weights was observed in all feno-
fibrate treated mice reaching up to 160% of untreated control
livers (data not shown), thus reflecting the peroxisome prolif-
erator property of fibrates in rodents. Furthermore, mRNA
levels of ACO, the rate-limiting enzyme in peroxisomal 
 
b
 
-oxi-
dation, whose induction by fibrates is strictly PPAR mediated
(42), increased approximately sixfold both in transgenic and
nontransgenic mice after fenofibrate administration (Fig. 2 
 
B
 
).
To exclude the possibility that the effect of fenofibrate on
human apo A-I gene expression is due to the site of transgene
integration, we performed a complementary experiment using
a transgenic mice line containing a 2.2-kb human apo A-I ge-
nomic DNA fragment. In this transgenic mice line, human apo
A-I gene is also expressed in the liver (30). After 7 d of treat-
ment, human apo A-I mRNA levels were increased from
100
 
6
 
24 in untreated mice to 237
 
6
 
3 in fenofibrate-treated
mice (
 
P
 
 
 
,
 
 0.05). This increase in mRNA levels was associated
with an increase in plasma human apo A-I concentrations
reaching 1,360
 
6
 
630 mg/dl compared to 180
 
6
 
10 mg/dl in un-
treated mice (
 
P
 
 
 
,
 
 0.05). These results thus strongly suggest
that the induction of human apo A-I gene expression by feno-
fibrate is independent of the site of transgene integration and
furthermore that the 
 
cis
 
-element mediating the response to
fenofibrate is present in the 2.2-kb genomic human apo A-I
DNA fragment.
 
Dose- and time-dependent effects of fenofibrate. 
 
Fenofi-
brate treatment increased plasma human apo A-I concentra-
tion in a dose-dependent fashion, attaining maximal effects at
a dose of 0.5% (Fig. 3 
 
A
 
). At the lowest dose (0.005%) of
fenofibrate tested, plasma human apo A-I and HDL-choles-
terol levels as well as liver apo A-I and ACO mRNA levels
were not affected. At a dose of 0.05% of fenofibrate both
plasma human apo A-I and HDL-cholesterol levels were in-
 
Table I. Influence of Fenofibrate on Plasma apo A-I 
Concentrations in Transgenic and Nontransgenic Mice
 
Treatment
hA-I mA-I
Transgenic mice Nontransgenic mice
 
mg/dl mg/dl
 
Control Before 215
 
6
 
73 100
 
6
 
19
After 288
 
6
 
90 118
 
6
 
22
Fenofibrate Before 370
 
6
 
60 103
 
6
 
13
After 3,174
 
6
 
117* 61
 
6
 
7*
Mice were treated 7 d with fenofibrate 0.5% (wt/wt) mixed in mouse
chow. Plasma apo A-I concentrations were determined before the treat-
ment and at the end of the experiments. Apo A-I levels are the
mean
 
6
 
SD of five animals. *
 
P
 
 
 
, 
 
0.01 (ANOVA).
 
Table II. Plasma Total Cholesterol and HDL-cholesterol 
Levels in hA-I Transgenic and Nontransgenic Mice Treated for 
7 d with Fenofibrate (0.5% wt/wt)
 
Treatment Total cholesterol HDL cholesterol
 
mg/dl mg/dl
 
Transgenic mice
Before 173
 
6
 
14 149
 
6
 
12
After 454
 
6
 
24* 450
 
6
 
20*
Nontransgenic mice
Before 84
 
6
 
5 66
 
6
 
3
After 92
 
6
 
11 64
 
6
 
7
Plasma cholesterol concentrations were determined before the treat-
ment and at the end of the experiments. Values are the mean
 
6
 
SD of
five animals. *
 
P
 
 
 
,
 
 0.05 (ANOVA).
Figure 1. Distribution of cholesterol in plasma of transgenic mice be-
fore and after treatment with fenofibrate. Animals were treated for 
7 d with fenofibrate 0.5%. Plasma collected from mice before and af-
ter the treatment was analyzed by gel filtration chromatography as 
described in Methods. The eluted fractions were assessed for choles-
terol concentrations.
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creased to 175 and 218% of controls, respectively (Fig. 3, 
 
A
 
and 
 
B
 
). These increases were correlated with a 35% increase
in hepatic human apo A-I mRNA levels (Fig. 3 
 
C
 
). At this
0.05% dose a 2.5-fold increase in ACO mRNA levels (Fig. 3 
 
D
 
)
and a small increase in liver weights could also be observed,
thereby paralleling the dose-dependent effects of fenofibrate
on apo A-I expression.
When mice were treated with fenofibrate 0.5% for differ-
ent periods of time, plasma human apo A-I and HDL-choles-
terol levels were increased (151 and 160% of controls, respec-
tively) after 3 d of fenofibrate treatment (Fig. 4, 
 
A
 
 and 
 
B
 
).
Human apo A-I and ACO mRNA levels were already in-
creased (72 and 510%, respectively) after 1 d of fenofibrate
treatment (data not shown), indicating that the increase in
plasma levels follows the increase in apo A-I gene expression.
 
Effect of fenofibrate on hepatic apo A-I gene transcription
rates.
 
To assess the effect of fenofibrate on apo A-I gene tran-
scription rate, nuclear run-on transcription assays were per-
formed on transgenic and nontransgenic mice, untreated (con-
trol) or treated for 5 d with fenofibrate 0.5% (wt/wt). A 300%
increase in human apo A-I gene transcription rate was ob-
served in transgenic mice treated with fenofibrate, whereas the
transcription rate of mouse apo A-I gene was decreased to 68
and 49% in transgenic and nontransgenic mice, respectively, in
response to fenofibrate (Fig. 5).
 
Effect of gemfibrozil on apo A-I expression.
 
Next we inves-
tigated whether the observed regulation of plasma apo A-I
and hepatic apo A-I gene expression was a general property of
all fibrates. Therefore, human apo A-I transgenic mice were
treated for 7 d with gemfibrozil at 0.5%, a dose found optimal
for fenofibrate and previously shown to be active in rodents (24).
 When mice were treated with gemfibrozil, plasma human
apo A-I and HDL-cholesterol levels were increased by 32 and
73%, respectively (Fig. 6, 
 
A
 
 and 
 
B
 
). The increase in HDL-cho-
lesterol was accompanied by a shift to larger particles as ob-
served with fenofibrate (data not shown). In addition, a 42%
decrease in murine apo A-I mRNA levels was measured (Fig.
6 
 
C
 
), whereas human apo A-I mRNA levels tended to in-
crease. Thus, gemfibrozil seems to have an intermediate im-
pact on apo A-I expression. This was also reflected by a less
marked effect of gemfibrozil on ACO mRNA levels (Fig. 6 
 
D
 
).
 
Fenofibric acid increases apo A-I gene expression in pri-
mary human hepatocytes. 
 
We previously reported that in rat,
apo A-I gene expression was decreased due to a direct effect
of fenofibric acid on hepatic cells (25). In view of the differen-
tial in vivo regulation of murine and human apo A-I in trans-
genic mice and to extend our observations in transgenic mice
to the human situation, we decided to investigate whether the
effect of fenofibric acid on human apo A-I gene expression
could also be observed using primary cultures of adult human
hepatocytes. Treatment of human hepatocytes for 72 h with
fenofibric acid resulted in an 83% increase in secreted apo A-I
only at the highest concentration of fenofibric acid (500 
 
m
 
M)
(Fig. 7 
 
A
 
). This increase was associated with a 50% increase in
apo A-I mRNA levels (Fig. 7 
 
B
 
). Secretion of apo A-II was
also induced by fenofibric acid 100 
 
m
 
M, thereby confirming
previous results (43). To assess the specificity of action of
fenofibric acid, different hepatic proteins were measured in
the supernatant of human hepatocytes. Transferrin secretion
as well as mRNA levels remained constant upon treatment
with fenofibric acid (Fig. 7, 
 
A
 
 and 
 
B
 
). As additional controls,
the concentrations of albumin, haptoglobin, and ceruloplasmin
were determined and were found to be unaffected by treat-
ment with fenofibric acid (data not shown).
These results therefore demonstrate that, in contrast to ro-
dent hepatocytes, fibrates increase human apo A-I gene ex-
Figure 2. Effect of fenofibrate on liver apo A-I mRNA levels in hu-
man apo A-I transgenic (Tg) and control mice. Mice were treated for 
7 d with fenofibrate 0.5% (wt/wt) mixed in mouse chow. Total RNA 
was extracted from liver and human apo A-I (hA-I) and mouse apo 
A-I (mA-I) mRNA levels were measured after dot blot hybridization. 
(A) Bar graph shows hA-I and mA-I mRNA levels in control and 
fenofibrate-treated transgenic and nontransgenic mice. Values repre-
sent the mean6SD of five animals. Statistically significant differences 
from controls (ANOVA, P , 0.05) are indicated by an asterisk. (B) 
Northern blot analysis. 10 mg of total mRNA was subjected to elec-
trophoresis, transferred to a nylon membrane, and hybridized with 
different probes as described in Methods.
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pression in human hepatocytes, indicating that human liver
also contains the necessary elements for apo A-I activation by
fibrates.
 
Discussion
 
Transgenic models have been widely used to investigate the
pro- or anti-atherogenic properties of human apolipoproteins
(4, 44–47). Overexpression of human apo A-I not only protects
the C57BL/6 susceptible strain of mice against early athero-
genesis but is also sufficient to counteract the atherogenic
properties of apo (a) (48) or the development of advanced ath-
erosclerotic lesions in apo E knockout mice (49, 50). In view of
these data, we can speculate that the modulation, i.e., up-regu-
lation, of apo A-I gene expression could also exert a profound
and beneficial impact on human atherosclerosis. The 5
 
9
 
 flank-
ing region of the human apo A-I gene has been demonstrated
to function as a liver transcriptional enhancer (51), and several
 
trans
 
-acting factors which are nuclear receptors have been
shown to interact with the apo A-I gene promoter to modulate
gene expression (52–58). However, since most reports are
based on in vitro methods, we decided to take advantage of the
human apo A-I transgenic mice to investigate the regulation of
human apo A-I gene expression in an in vivo context. It has
Figure 3. Dose-dependent effects 
of fenofibrate on plasma human 
apo A-I (A) and HDL cholesterol 
levels (B) and on liver human and 
mouse apo A-I (C) and ACO (D) 
mRNA levels in hA-I transgenic 
mice. Animals were treated for 7 d 
with the indicated doses of fenofi-
brate. Plasma human apo A-I and 
HDL-cholesterol concentrations 
were measured before and after 
treatment as described in Meth-
ods. Each value represent the 
mean6SD of eight animals. Statis-
tically significant differences from 
controls (ANOVA, P , 0.05) are 
indicated by an asterisk. Liver 
RNA was extracted; human and 
mouse apo A-I and ACO mRNA 
levels were measured by dot blot 
analysis as described in Methods. 
Each value represents the 
mean6SD of five animals.
Figure 4. Time-dependent effects 
of fenofibrate on plasma human 
apo A-I and HDL cholesterol lev-
els in hA-I transgenic mice. Mice 
were treated with fenofibrate 
0.5% for the indicated periods of 
time. Before and at the end of the 
treatment, blood was taken and 
human apo A-I (A) as well as 
HDL cholesterol levels (B) were 
measured as described in Meth-
ods. Each value represents the 
mean6SD of 10 animals. Statisti-
cally significant differences from 
controls (ANOVA, P , 0.005) 
are indicated by an asterisk.
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been previously demonstrated that high fat diet increases
HDL particle concentrations and apo A-I transport rates in
hA-I transgenic mice (59). Another study using hA-I trans-
genic mice to examine the effect of probucol on lipid parame-
ters showed a decrease in HDL-cholesterol concentrations and
apo A-I transport rate (60).
In rats, fenofibrate induces a decrease in HDL-cholesterol
concentrations (8) as well as in apo A-I mRNA levels (24).
The down-regulation of apo A-I gene expression reported in
rat is reproduced in our murine model since liver endogenous
apo A-I mRNA levels are decreased in transgenic and non-
transgenic mice treated with fenofibrate. In humans, however,
treatment with fenofibrate increases plasma HDL-cholesterol
and apo A-I levels (6, 26, 27), but the molecular mechanisms of
this induction remains unclear. The results from this study
show that fibrates increase plasma HDL and human apo A-I
Figure 5. Effect of fenofibrate on hepatic apo A-I gene transcription rate. Nuclear run-on assays were performed on transgenic and nontrans-
genic mice treated for 5 d with fenofibrate 0.5% (wt/wt) mixed in mouse chow and compared to untreated (control) mice.
Figure 6. Comparison of the ef-
fects of gemfibrozil and fenofi-
brate on plasma apo A-I (A) and 
HDL-cholesterol (B) levels and 
on liver apo A-I (C) and ACO (D) 
mRNA levels in hA-I transgenic 
mice. Animals were treated with 
0.5% of fenofibrate or gemfibrozil 
for 7 d. Plasma human apo A-I 
and HDL-cholesterol concentra-
tions were measured before and 
after the treatment period. Each 
value represents the mean6SD of 
five animals. Human and mouse 
apo A-I and ACO mRNA levels 
were measured by dot blot analy-
sis as described in Methods. Statis-
tically significant differences from 
controls (ANOVA, P , 0.05) are 
indicated by an asterisk.
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concentrations as well as liver human apo A-I mRNA levels in
transgenic mice. This increase in human apo A-I mRNA level
is due to an increase in the transcription rate as demonstrated
by run-on transcription assays. In addition, experiments on a
second transgenic mice line demonstrate that the effect of
fenofibrate on human apo A-I gene expression is not due to
the site of transgene integration, but requires a cis-element
present in the 2.2-kb fragment, which extends from 256 bp 59
to 80 bp 39 of the human apo A-I gene and contains the liver-
specific enhancer (30). Furthermore, experiments on isolated
human hepatocytes, showing an increase in apo A-I secretion
and apo A-I mRNA levels, support the hypothesis that the in-
crease in circulating apo A-I observed in fenofibrate-treated
patients results, at least partially, from a direct effect on liver
apo A-I gene expression. A previous report demonstrated that
fenofibrate also increases apo A-I synthesis in the human
HepG2 hepatoma cell line (61). In humans, a modest but sig-
nificant increase in plasma apo A-I levels after fenofibrate
treatment has been reported (6, 27). Interestingly, our study
shows that human apo A-I response to fibrates is amplified in
hA-I transgenic mice. The dramatic increase in plasma apo A-I
may be a consequence of the high basal expression due to the
presence of a high number of human apo A-I gene copies in
the transgenic mice. Indeed, apo A-I concentration in human
plasma is z 100 mg/dl, whereas human plasma apo A-I levels
in transgenic mice are ranging from 200 to 400 mg/dl. Alterna-
tively, it cannot be excluded that fibrates, in addition to their
effects on apo A-I gene transcription, exert posttranscriptional
effects on plasma HDL and apo A-I metabolism and may af-
fect the rates of catabolism of human apo A-I-containing HDL
particles.
Despite the opposite regulation of murine and human apo
A-I gene expression after fenofibrate treatment, an increase in
liver weight is observed in both hA-I transgenic and control
mice. Moreover, the induction of human apo A-I gene expres-
sion was accompanied by a strong dose-dependent induction
of ACO gene expression, the rate-limiting enzyme in the path-
way of the peroxisomal b-oxidation of fatty acids. Fibrates ac-
tivate specific receptors, called PPARs, which interact with
specific response elements, termed peroxisome proliferator re-
sponse elements (PPREs), in the regulatory sequences of tar-
get genes, such as ACO (20, 62). A functional PPRE, which is
transactivated by PPARa in transient cotransfection assays,
has been identified in the A-site of the liver-specific enhancer
in the apo A-I gene promoter (52). Our study performed in
transgenic animals containing, in addition to the endogenous
mouse apo A-I gene, an 11- or a 2.2-kb human apo A-I ge-
nomic DNA fragment, suggests that the opposite effects of fi-
brates on human and rodent apo A-I gene transcription are
mediated through distinct elements present in cis. Further-
more, the experiments performed in human hepatocytes dem-
onstrate that human liver, as well as mouse liver, contains the
necessary trans-factors to mediate the induction of apo A-I ex-
pression by fibrates.
This up-regulation of human apo A-I gene expression after
fenofibrate treatment, which occurs at the transcriptional level
as demonstrated by run-on transcription assays, may be, at
least partially, PPAR mediated. Conversely, the down-regula-
tion of rodent apo A-I gene expression after fibrate treatment
could be explained by the presence of a nonfunctional PPRE
in the rodent apo A-I gene promoter, since it has been demon-
strated that, compared to the human A-site, the rat apo A-I
A-site contains three base-pair changes which prevent
PPARa/RXRa binding (63). In absence of a functional PPRE,
fibrates may decrease rodent apo A-I transcription by down-
regulating the expression of the positive hepatic transcription
factor HNF-4 (64). Alternatively, rodent apo A-I gene tran-
scription may be decreased after fibrates by a mechanism in-
volving negative fibrate regulatory elements located in the
basal apo A-I gene promoter (52).
Another fibrate, gemfibrozil, was also efficient in increas-
ing human apo A-I plasma concentrations in transgenic mice,
but to an intermediate level compared to fenofibrate. Further-
more, quantitatively distinct effects between gemfibrozil and
fenofibrate were observed on human apo A-I as well as ACO
mRNA levels in liver. The less pronounced effect of gemfi-
brozil on ACO mRNA levels was also observed in rats (7).
Human apo A-I gene regulation in response to different fi-
Figure 7. Effect of fenofibric 
acid on apo A-I, apo A-II, and 
transferrin secretion (A) and 
mRNA levels (B) in primary 
cultures of adult human hepa-
tocytes. Human hepatocytes 
were isolated and treated with 
fenofibric acid 100 or 500 mM 
or vehicle (control; DMSO) for 
72 h as described in Methods. 
(A) Bar graph shows human 
apo A-I, A-II, and transferrin 
secreted in the culture me-
dium. After a 72-h treatment 
period, the concentration of 
different proteins was mea-
sured by ELISA as described 
in Methods. Data are 
mean6SD of three replicates. 
Statistically significant differ-
ences from controls (ANOVA, P , 0.01) are indicated by an asterisk. (B) Northern blot analysis. Total cellular RNA was extracted, and 10 mg 
of total RNA was subjected to electrophoresis, transferred to a nylon membrane, and hybridized with the indicated probes as described in 
Methods.
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brates probably results from a subtle balance between their ef-
fects on the negative regulatory elements in the basal gene
promoter and the PPAR-dependent positive regulation of apo
A-I gene expression (52).
In addition to their effects on apo A-I gene transcription,
different fibrates may elicit different metabolic responses. In-
deed, both in rodents (65, 66) as well as in humans (28, 29),
gemfibrozil has been shown to be a more potent HDL inducer
than the other clinically used fibrates. Gemfibrozil, unlike
other fibrates, has also been shown to increase plasma apo E
concentrations (24, 66). Fibrates and other peroxisome prolif-
erators clearly exhibit a wide array of biological activities and
potential side-effects both in rodents and in humans (67). In
particular, the impact of fibrates on HDL metabolism is obvi-
ously not restricted to apo A-I, since several clinical studies ev-
idenced an increase in plasma apo A-II concentrations in feno-
fibrate-treated patients (6, 27, 43). This induction is due to a
fenofibrate-mediated increase of human apo A-II gene tran-
scription in HepG2 cells as well as in primary human hepato-
cytes, which is mediated by the interaction of PPAR with a PPRE
located in the J site of the apo A-II promoter (43). Since Lp A-I
are considered to be better protectors against atherosclerosis
than Lp A-I/A-II (1), the increase in apo A-II expression
might be considered to be an adverse property of fibrates (67).
Taken together, our data indicate that transgenic mice pro-
vide a unique and powerful means to investigate in vivo gene
regulation of human apolipoproteins. The transgenic model
can be used not only to extend the in vitro characterization of
apolipoprotein gene promoters, but also to dissect the mecha-
nisms underlying the antiatherogenic properties of hypolip-
idemic drugs. Since we recently produced transgenic rabbits
expressing human apo A-I in the liver (68), the consequences
of apo A-I induction by fibrates on the development of athero-
sclerosis could be further studied in this rabbit model, which is
more relevant for human atherosclerosis. Finally, other trans-
genic models, such as mice expressing the human apo A-I and
apo A-II genes under the control of their respective promot-
ers, could be generated to delineate the pharmacological prop-
erties of drugs, such as fibrates, on different human apolipo-
proteins in one single animal model.
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